All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Mohammed Kharfan-Dabaja of the Moffitt Cancer Center in Tampa, Florida, and colleagues investigated outcomes in Gray Zone Lymphoma (GZL) patients after autologous stem cell transplant. The findings were published online December 7, 2017, in the journal Biology of Blood and Marrow Transplantation.
Gray Zone Lymphoma has features which are intermediate between Diffuse Large B-Cell Lymphoma and classical Hodgkin’s Lymphoma. GZL is very rare, and there is no standard treatment recommendation for this diagnosis. The goal of this study was to review therapy outcomes for relapsed or refractory GZL after autologous stem cell transplant (SCT).
These findings suggest that autologous transplant may be a suitable treatment option for Gray Zone Lymphoma. The results of this observation should be validated in a larger, prospective study, to confirm outcomes of autologous transplant in this population.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox